ArticleInternational journal of clinical and experimental pathology2018
Impact of AQP-5 on the growth of colorectal cancer cells and the underlying mechanism.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Aquaporins in colorectal cancer: exploring their role in tumorigenesis, metastasis, and drug response.Human cell · 2024Review
- Article
- Combined pharmacological administration of AQP1 ion channel blocker AqB011 and water channel blocker Bacopaside II amplifies inhibition of colon cancer cell migration.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aquaporin 5 (AQP-5) is highly expressed in colorectal cancer tissue and associated with colorectal cancer development and prognosis. Here, we explored the effects of AQP-5 on colorectal cancer cell proliferation and apoptosis and the underlying mechanism by inhibiting endogenous AQP-5 expression in the human colorectal cancer cell lines COLO 205 and SW480. These cells were transfected with an AQP-5-siRNA, and transfection efficiency and its effects on AQP-5 expression were assessed by immunofluorescence and PCR, respectively. Then, cell proliferation was assessed via the MTT assay, apoptosis was assessed by Annexin V-FITC/PI and TUNEL assays, and expression changes in Bax and Bcl-2 were assessed by RT-PCR and western blotting. Transfection with AQP-5-siRNA reduced AQP-5 expression by up to 62%. The MTT assay showed that cell proliferation was significantly inhibited by AQP-5-siRNA transfection compared to that in NS-siRNA-transfected cells (
Indexed as
Identifiers
31938087PMC6957951W3005860850What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.